Bioanalysis of Cepharanthine by LC-ESI-MS-MS and Its Application to Pharmacokinetic Studies

被引：8

作者：

Dong, Rui-Hua ^{[1
]}

Fang, Zhong-Ze ^{[2
,3
]}

Gao, Hong-Zhi ^{[1
]}

Hao, Guang-Tao ^{[1
]}

Liu, Guang ^{[1
]}

Shan, Ting-Ting ^{[1
]}

Liu, Ze-Yuan ^{[1
]}

机构：

[1] Acad Mil Med Sci, Affiliated Hosp, Dept Clin Pharmacol, Beijing 100071, Peoples R China

[2] Chinese Acad Sci, Dalian Inst Chem Phys, Lab Pharmaceut Resource Discovery, Dalian 116023, Peoples R China

[3] Chinese Acad Sci, Grad Sch, Beijing 100049, Peoples R China

来源：

CHROMATOGRAPHIA | 2011年 / 73卷 / 1-2期

关键词：

Column liquid chromatography-tandem mass spectrometry Pharmacokinetic study; Cepharanthine; DRUG-METABOLISM; DISCOVERY; CELLS;

D O I：

10.1007/s10337-010-1823-3

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

A sensitive liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS-MS) method was developed and validated for the quantification of cepharanthine (CEP) in beagle dog plasma. The chromatographic separation was performed on an Agilent-C18 column and the mobile phase was composed of methanol:water with 10 mM ammonium acetate (20:80, v/v). Detection was operated in the positive ion mode and the tandem mass spectrometer was tuned in the multiple reactions monitoring mode (MRM) to monitor m/z transitions 607 -> 365 for CEP and 285 -> 193 for the internal standard (IS) diazepam. This method exhibited a linear range of 5-2,500 ng mL(-1). The precision (RSD%) and accuracy (RME%) of the assay were < 8.7 and 2.4%, respectively. The limit of quantification was 5 ng mL(-1) and no significant matrix effect was observed. The validated method has been successfully applied to pharmacokinetic study of CEP in beagle dog.

引用

页码：75 / 81

页数：7

共 12 条

[1] ASAUMI J, 1995, ANTICANCER RES, V15, P67
[2] Bory S, 2010, NAT PROD COMMUN, V5, P877
[3] CEPHARANTHINE (BISCOCLAURINE ALKALOID) TREATMENT IN ENDOTOXIC-SHOCK OF SUCKLING RATS
GOTO, M
ZELLER, WP
HURLEY, RM
[J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 1991, 43 (08) : 589 - 591
[4] HIRAI M, 1995, J PHARMACOL EXP THER, V275, P73
[5] HPLC-MS/MS in drug metabolism and pharmacokinetic screening
Hsieh, Yunsheng
[J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2008, 4 (01) : 93 - 101
[6] KNODO Y, 1992, INT J IMMUNOPHARMACO, V14, P1181
[7] Lin JH, 1997, PHARMACOL REV, V49, P403
[8] Nagano Makoto, 2003, Physiological Chemistry and Physics and Medical NMR, V35, P131
[9] ONO M, 1994, CANCER CHEMOTH PHARM, V35, P10, DOI 10.1007/s002800050186
[10] SHIRAISHI N, 1980, PHYSIOL CHEM PHYS M, V12, P299

← 1 2 →